Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited.

In the trials in subthreshold anxiety disorder in which no specific depression scale was administered, Silexan was associated with a reduction of the treatment group mean value for depressed mood at or above 50% of the baseline value, notably in patients with at least moderate symptoms of depression at baseline, with significant superiority over placebo in two trials and a borderline significant result in the third, based on HAMA item ‘depressed mood’.

also in 11,409 other papers